AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16482238 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 10 days)
Number of subjects: 213
Study 16482238 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (esomeprazole 20 mg + amoxycillin 1 g for 5 days, followed by esomeprazole 20 mg, clarithromycin 500 mg, tinidazole 500 mg for 5 days)
Number of subjects: 213
Study 16482238 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 10-day sequential regimen vs 7-day triple therapy
Number of subjects: 213
Study 16482238 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 10-day sequential regimen vs 10-day triple therapy
Number of subjects: 213
Study 16482238 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 7-day triple therapy vs 10-day triple therapy
Number of subjects: 213
Study 12941449 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes Open in the Dark (EOd)
Number of subjects: 20
Study 12941449 — intervention group
Group type: COMPARATOR
Intervention: Eyes Closed (EC)
Number of subjects: 20
Study 12941449 — intervention group
Group type: COMPARATOR
Intervention: Eyes Open in Daylight (EO)
Number of subjects: 20
Study 10804906 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitors (SSRIs)
Number of subjects: 9
Study 10804906 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 9
Study 10804906 — intervention group
Group type: COMPARATOR
Intervention: Untreated PTSD patients
Number of subjects: 9
Study 8628043 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item linear analogue self-assessment scale for mood
Number of subjects: 2129
Study 8628043 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-item adjective checklist for emotional well-being
Number of subjects: 2129
Study 1634662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (continued smoking)
Number of subjects: 780
Study 1634662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking cessation (quitters)
Number of subjects: 780
Study 1634662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (continued smoking) in bypass surgery patients
Number of subjects: 780
Study 1634662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking cessation (quitters) in bypass surgery patients
Number of subjects: 780
Study 6823861 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (intravenous administration)
Number of subjects: 7
Study 6823861 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (prolonged oral therapy)
Number of subjects: 7
Study 6823861 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 7
Study 30817919 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol prophylaxis postoperatively
Number of subjects: 84
Study 30817919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 29405886 — intervention group
Group type: EXPERIMENTAL
Intervention: TIF 2.0 with EsophyX2 device
Number of subjects: 63
Study 27359325 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-HCC risk score based on age > 65 years, low triglyceride levels, and high gamma-glutamyl transferase levels
Number of subjects: 3544
Study 27359325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidences of HCC
Number of subjects: 3544
Study 27359325 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years, low triglyceride levels, high gamma-glutamyl transferase levels
Number of subjects: 3544
Study 27359325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model
Number of subjects: 3544
Study 25719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of an address by a trained teacher, a video show, and a leaflet given to each pupil
Number of subjects: 60
Study 25719902 — intervention group
Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 60
Study 25719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 60
Study 23696676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 203
Study 23696676 — intervention group
Group type: COMPARATOR
Intervention: Two pills (angiotensin II receptor blocker and thiazide diuretic)
Number of subjects: 203
Study 19828203 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Number of subjects: 573
Study 18154823 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g)
Number of subjects: 182
Study 18154823 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (0.8 microg/kg bolus and 0.113 microg/kg/h infusion)
Number of subjects: 182
Study 18154823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methylprednisolone and triiodothyronine
Number of subjects: 182
Study 18154823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 18154823 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial management
Number of subjects: 182
Study 16869873 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA 15 J/cm(2)
Number of subjects: 20
Study 16869873 — intervention group
Group type: COMPARATOR
Intervention: UVA 5 J/cm(2)
Number of subjects: 20
Study 14708610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B sunscreen (sun protection factor 5.2)
Number of subjects: 75
Study 14708610 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum ultraviolet A + B sunscreen (sun protection factor 6.2)
Number of subjects: 75
Study 14708610 — intervention group
Group type: COMPARATOR
Intervention: Control (no sunscreen)
Number of subjects: 75
Study 11132506 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications ranked by quality of evidence
Number of subjects: 2848
Study 9165973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg.kg‐1
Number of subjects: 0
Study 9165973 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg.kg‐1
Number of subjects: 0
Study 9165973 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 1547191 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 1 g/day (4 tablets)
Number of subjects: 17
Study 1547191 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 250 mg/day (1 tablet)
Number of subjects: 17
Study 1547191 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole study group
Number of subjects: 17
Study 4059587 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg nalmefene
Number of subjects: 6
Study 4059587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30259252 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-coated mesh
Number of subjects: 102
Study 30259252 — intervention group
Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 102
Study 30594227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of Tranexamic acid (TXA) by intravenous injection immediately after the umbilical cord is cut or clamped
Number of subjects: 10000
Study 30594227 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10000
Study 26524725 — intervention group
Group type: COMPARATOR
Intervention: Home-based intervention program (HBIP)
Number of subjects: 178
Study 26524725 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based intervention program (CBIP)
Number of subjects: 178
Study 24557112 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O (FIO2 = 0.5)
Number of subjects: 50
Study 24557112 — intervention group
Group type: COMPARATOR
Intervention: O2 (100% oxygen)
Number of subjects: 50
Study 24557112 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2 mixture (FIO2 = 0.5)
Number of subjects: 50
Study 21839467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild fluid restriction
Number of subjects: 64
Study 21839467 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid management
Number of subjects: 64
Study 20141565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 40,000 IU per week (DD group)
Number of subjects: 438
Study 20141565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 20,000 IU per week (DP group)
Number of subjects: 438
Study 20141565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP group)
Number of subjects: 438
Study 18678826 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 mg/d EPA-DHA for 26 weeks
Number of subjects: 302
Study 18678826 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d EPA-DHA for 26 weeks
Number of subjects: 302
Study 18678826 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 302
Study 15672985 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 100 mg, 200 mg, 100 mg, and 200 mg administered at 21:45, 23:45, 01:45, and 03:45
Number of subjects: 30
Study 15672985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 30
Study 15672985 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 30
Study 12799091 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/d
Number of subjects: 118
Study 12799091 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/d
Number of subjects: 118
Study 12799091 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 2 x 50 mg/d
Number of subjects: 118
Study 10232433 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements of the liver (T2 relaxation time)
Number of subjects: 21
Study 10232433 — intervention group
Group type: EXPERIMENTAL
Intervention: Average serum ferritin levels
Number of subjects: 21
Study 10232433 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC (% predicted)
Number of subjects: 21
Study 8038755 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF (0.01 fmol/Kg/min)
Number of subjects: 20
Study 8038755 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (50 mL of isotonic saline)
Number of subjects: 20
Study 2662830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 300 mg of pentoxifylline (15 mL ampoules) administered over three hours twice daily.
Number of subjects: 154
Study 2662830 — intervention group
Group type: COMPARATOR
Intervention: Placebo: 15 mL of a 0.9% NaCl solution in 250 mL of 5% laevulose, administered over three hours twice daily.
Number of subjects: 154
Study 4581347 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg single dose)
Number of subjects: 5
Study 4581347 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (30 mg three times a day for one month)
Number of subjects: 5
Study 4581347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30745260 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) for 2 months
Number of subjects: 48
Study 30745260 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study 30745260 — intervention group
Group type: COMPARATOR
Intervention: Both groups (nVNS and sham)
Number of subjects: 48
Study 30745260 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) and sham stimulation
Number of subjects: 48
Study 23604570 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy at 5 mg/kg initially given at 0, 2, 6 weeks, then at 8-week intervals.
Number of subjects: 57
Study 23604570 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) as an indicator.
Number of subjects: 57
Study 23604570 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) >0.5 mg/dL.
Number of subjects: 57
Study 23604570 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to loss of response (LOR).
Number of subjects: 57
Study 23107346 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine + placebo
Number of subjects: 14
Study 23107346 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + placebo
Number of subjects: 14
Study 23107346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20131184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of 20 ml of bone marrow cells (BMC) after successful primary PCI
Number of subjects: 40
Study 20131184 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stenting of the infarct-related artery (IRA) without BMC administration
Number of subjects: 40
Study 20131184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of 20 ml of BMC
Number of subjects: 40
Study 18167502 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 160
Study 18167502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 16173965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 14522731 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30:40:30 ratio of protein to carbohydrate to fat)
Number of subjects: 12
Study 14522731 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 12
Study 14522731 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15:55:30 ratio of protein to carbohydrate to fat)
Number of subjects: 12
Study 14522731 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study 10908007 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week Matrix program
Number of subjects: 0
Study 10908007 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment offered by the programs at the eight participating sites
Number of subjects: 0
Study 9461944 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/kg ketamine
Number of subjects: 60
Study 9461944 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml/kg of standard oral premedication (SOP)
Number of subjects: 60
Study 14621723 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal immunoglobulins (mIg) identified by agarose gel electrophoresis and immunofixation
Number of subjects: 192
Study 14621723 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified predisposing factors for mIg emergence
Number of subjects: 192
Study 14621723 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological evidence for active EBV infection
Number of subjects: 192
Study 14621723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical course of patients with mIg
Number of subjects: 192
Study 14621723 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory T-cell function
Number of subjects: 192
Study 2864892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (11 mg)
Number of subjects: 4
Study 2864892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethonium (910 mg)
Number of subjects: 4
Study 2864892 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg)
Number of subjects: 4
Study 2864892 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4
Study 2864892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30621047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanghuang⁻Danshen (SD) bioactives at 900 mg/day for 4 weeks
Number of subjects: 72
Study 28657863 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake (50g glucose before each training bout)
Number of subjects: 23
Study 28657863 — intervention group
Group type: COMPARATOR
Intervention: No carbohydrate intake (control)
Number of subjects: 23
Study 26725922 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope
Number of subjects: 30
Study 26725922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils intubation fiberscope
Number of subjects: 30
Study 26725922 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 30
Study 24473467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and high-intensity training (S group)
Number of subjects: 24
Study 24473467 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 24
Study 22791244 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (dispersible tablet)
Number of subjects: 18
Study 22791244 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (branded capsule)
Number of subjects: 18
Study 20112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37663 (4 mg/day)
Number of subjects: 0
Study 20112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37663 (15 mg/day)
Number of subjects: 0
Study 20112368 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 37663 (50 mg/week)
Number of subjects: 0
Study 20112368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18173153 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM treatment for dissolving phlegm and dispelling stasis (DP‐DS)
Number of subjects: 122
Study 18173153 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 122
Study 16248138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive imaging as a teaching method
Number of subjects: 42
Study 16248138 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructional techniques
Number of subjects: 42
Study 11896446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-IL-2 (5x10^5 cells)
Number of subjects: 28
Study 11896446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-IL-2 (5x10^6 cells)
Number of subjects: 28
Study 11896446 — intervention group
Group type: COMPARATOR
Intervention: Vero-IL-2 (both doses)
Number of subjects: 28
Study 10629245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 10629245 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 9019380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml Healon injected
Number of subjects: 0
Study 9019380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml Healon injected
Number of subjects: 0
Study 9019380 — intervention group
Group type: COMPARATOR
Intervention: Healon aspirated
Number of subjects: 0
Study 1761331 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (intervention)
Number of subjects: 0
Study 6803118 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0
Study 6803118 — intervention group
Group type: COMPARATOR
Intervention: Control (ad libitum intake)
Number of subjects: 0
Study 30864054 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine dependence (measured by FTND)
Number of subjects: 255
Study 30864054 — intervention group
Group type: EXPERIMENTAL
Intervention: Expired CO levels
Number of subjects: 255
Study 30864054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared to change
Number of subjects: 255
Study 30864054 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence to quit
Number of subjects: 255
Study 29900874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg orally twice daily
Number of subjects: 1754
Study 29900874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1754
Study 27692272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly for 12 months
Number of subjects: 95
Study 27692272 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 12 months
Number of subjects: 95
Study 24588623 — intervention group
Group type: COMPARATOR
Intervention: Inflow tract implantation
Number of subjects: 80
Study 24588623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-septum implantation
Number of subjects: 80
Study 22738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine-based acupuncture
Number of subjects: 50
Study 22738796 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with Streitberger placebo needles
Number of subjects: 50
Study 20647199 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² per week for 4 weeks)
Number of subjects: 197
Study 20647199 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (2 mg/kg per day)
Number of subjects: 197
Study 17209171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D dose > or = 250 microg/d (10,000 IU vitamin D3)
Number of subjects: 0
Study 17209171 — intervention group
Group type: COMPARATOR
Intervention: Current UL for vitamin D (50 microg, or 2000 IU)
Number of subjects: 0
Study 16275247 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 21
Study 16275247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12019667 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 37
Study 12019667 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 37
Study 10633642 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening intervention
Number of subjects: 30
Study 10633642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music listening)
Number of subjects: 30
Study 7546499 — intervention group
Group type: COMPARATOR
Intervention: enalapril/placebo (group I)
Number of subjects: 296
Study 7546499 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg enalapril/HCTZ (group II)
Number of subjects: 296
Study 7546499 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg enalapril/HCTZ (group III)
Number of subjects: 296
Study 2187213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (mean daily dose of 7 mg)
Number of subjects: 67
Study 2187213 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose of 3 mg)
Number of subjects: 67
Study 2187213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 213186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment in addition to conventional therapy (surgery, radiotherapy or no treatment)
Number of subjects: 75
Study 213186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment with a full course of radiotherapy
Number of subjects: 75
Study 213186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment in patients with squamous carcinoma
Number of subjects: 75
Study 213186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG treatment in patients with oat cell carcinoma
Number of subjects: 75